Clinical Trials
64 trialsNCT07629817 2026-06-05
HCHTOG2603
Henan Cancer Hospital
Phase 3 Not yet recruiting
NCT07621601 2026-06-02
A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)
Hansoh BioMedical R&D Company
Phase 3 Not yet recruiting
NCT04210115 2026-05-13
KEYNOTE 975
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04550260 2026-05-13
KUNLUN
AstraZeneca
Phase 3 Active not recruiting
NCT05357846 2026-04-30
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
Sun Yat-sen University
Phase 3 Recruiting
NCT07463573 2026-04-24
QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT07177794 2026-04-21
EC-CRT-008
Sun Yat-sen University
Phase 3 Recruiting
NCT04543617 2026-04-17
SKYSCRAPER-07
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT06304974 2026-04-17
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT03957590 2026-04-13
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
BeOne Medicines
Phase 3 Completed
NCT06952621 2026-01-30
TD-NEOE3V3
Tang-Du Hospital
Phase 3 Not yet recruiting
NCT06644781 2026-01-12
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
Daiichi Sankyo
Phase 3 Recruiting
NCT04949256 2025-12-15
MK-7902-014
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT07246330 2025-11-24
Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Not yet recruiting
NCT03783442 2025-07-29
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
BeiGene
Phase 3 Completed
NCT07016737 2025-06-12
ESO-Nanjing12
Jiangsu Cancer Institute & Hospital
Phase 3 Enrolling by invitation
NCT05078047 2025-06-05
MOIO
UNICANCER
Phase 3 Recruiting
NCT04328948 2025-05-22
ARMADILLO
National Cancer Center, Japan
Phase 3 Recruiting
NCT04460352 2025-03-06
NEEDS
Karolinska University Hospital
Phase 3 Recruiting
NCT06775652 2025-01-15
ESCC
Sichuan Cancer Hospital and Research Institute
Phase 3 Completed
NCT05919030 2024-11-14
A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma
Renmin Hospital of Wuhan University
Phase 3 Recruiting
NCT03430843 2024-10-26
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
BeiGene
Phase 3 Completed
NCT05495152 2024-10-02
Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma
Henan Cancer Hospital
Phase 3 Recruiting
NCT06022861 2024-09-19
A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Shandong Boan Biotechnology Co., Ltd
Phase 3 Recruiting
NCT06563869 2024-08-21
Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 3 Recruiting
NCT06501664 2024-07-15
Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT06190782 2024-05-02
Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
Fudan University
Phase 3 Recruiting
NCT06194734 2024-03-07
A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
Beijing Konruns Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT05737563 2024-01-23
Escape
Sun Yat-sen University
Phase 3 Unknown
NCT02465736 2024-01-16
Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)
Sun Yat-sen University
Phase 3 Unknown
NCT04187352 2023-11-24
A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma
CStone Pharmaceuticals
Phase 3 Completed
NCT03748134 2023-10-24
Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT03790553 2023-08-03
Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma
Fudan University
Phase 3 Unknown
NCT03958890 2023-04-18
A Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)
Shanghai Henlius Biotech
Phase 3 Unknown
NCT02025036 2023-02-08
CRTCOESC
The First Affiliated Hospital of Henan University of Science and Technology
Phase 3 Unknown
NCT05244798 2022-10-25
Sintilimab Plus NCT or NCRT Versus NCRT for ESCC
Sichuan Cancer Hospital and Research Institute
Phase 3 Not yet recruiting
NCT04138212 2022-08-09
HCHTOG1903
Henan Cancer Hospital
Phase 3 Recruiting
NCT00655876 2022-06-14
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT04807673 2022-06-01
KEYSTONE-002
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Recruiting
NCT01137123 2022-03-31
Improve the Treatment of Thoracic Esophageal Cancer
Sun Yat-sen University
Phase 3 Completed
NCT02459457 2022-02-09
A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer
Fudan University
Phase 3 Completed
NCT04009265 2021-11-12
Study Compare Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone for pN1-2(pT1b-3N1-2M0) Esophageal Carcinoma
Fujian Medical University Union Hospital
Phase 3 Recruiting
NCT04196075 2021-11-08
AP
Chinese University of Hong Kong
Phase 3 Completed
NCT02644408 2021-02-17
Megestrol Acetate for the Improvement of Quality of Life in Esophageal Cancer With Chemoradiotherapy
The First Affiliated Hospital of Henan University of Science and Technology
Phase 3 Completed
NCT01107639 2020-10-20
Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery
Swiss Cancer Institute
Phase 3 Completed
NCT00047112 2020-03-30
Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer
Federation Francophone de Cancerologie Digestive
Phase 3 Completed
NCT02399306 2020-03-17
Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma
Sichuan Cancer Hospital and Research Institute
Phase 3 Completed
NCT01591135 2018-10-18
A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma
Fudan University
Phase 3 Completed
NCT01627379 2018-03-02
POWER
AIO-Studien-gGmbH
Phase 3 Terminated
NCT03273647 2017-10-19
Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma With Positive Circumstantial Resection Margin
Fudan University
Phase 3 Unknown